Kanarbzet, Sogroya newly reimbursed next month

Opdivo 120mg and Nucala autoinjector have also been added to the reimbursement list

Pelubi’s price reduced by 29.3%, Erleada’s price reduced by 2%

Boryung Pharmaceutical’s triple-combination drug for hypertension and dyslipidemia, ‘Kanarbzet Tab,’ will be newly reimbursed from next month

Boryung Pharmaceutical’s triple-combination drug for hypertension and dyslipidemia, ‘Kanarbzet Tab,’ and Novo Nordisk Pharmaceutical’s long-acting growth hormone ‘Sogroya’ will be newly listed for reimbursement next month (May).

Viatris Isoptin Inj, Epic Cholestyramine Powder, and Senra 5-HTP, supplied through the Korea Orphan & Essential Drug Center, will also newly obtain reimbursement.

Ono Pharmaceutical’s Opdivo Inj(120 mg) and the autoinjector formulation of GSK’s Nucala will be newly listed for reimbursement, while Daewon Pharmaceutical’s Pelubi and Janssen’s Erleada will have their reimbursement price ceilings reduced.

LG Chem’s Zemidapa, which had been scheduled for a price reduction, will retain its current price.

On the 21st, the Ministry of Health and Welfare partially revised and issued the “Drug Reimbursement List and Reimbursement Price Ceiling Table” containing these changes.

Boryung’s Kanarbzet Tab, a combination of the antihypertensive drug Kanarb (containing fimasartan) and the hyperlipidemia drugs atorvastatin and ezetimibe, will be priced at KRW 1,644 per tablet for the 30/10/10 mg formulation, the 30/20/10-milligram formulation is KRW 1,646, the 60/10/10-milligram formulation is KRW 1,753, and the 60/20/10-milligram formulation is KRW 1,755.

Sogroya Prefilled Pen 15mg/1.5ml will be listed for reimbursement at KRW 277,624 per pen, and Opdivo Injection 120mg at KRW 1,318,822 per vial.

The price of Viatris Isoptin 5 mg Inj is set at KRW 3,491 per 2 ml vial, Epic Cholestyramine Powder for Susp at KRW 1,604 per 4 g packet, and Cenra 5-HTP 100 mg Cap at 2KRW 790 per capsule. The price of the Nucala autoinjector is set at KRW 1.28 million per pen, the same as the existing injectable formulation.

Among already listed drugs, Pelubi Tab and Pelubi SR Tab will have their reimbursement ceilings reduced by 46.7% and 23.0%, respectively, on the 1st of next month. 

Among these, the reimbursement ceiling for Pelubi SR Tab will be further reduced by 23.5% starting August 1.The reimbursement ceiling for Janssen’s Erleada Tab will also be reduced by 29.3% on the 1st of next month, while Kyowa Kirin’s Orkedia Tab 1 mg and 2 mg will each be reduced by 2.0%.

Kolon Pharmaceutical’s Kotuss 50 mg will be reduced by 0.4%, and Chong Kun Dang’s Dilatrend SR 32 mg by 0.1%

Meanwhile, Zemidapa Tab, which had been scheduled for a 15.5% reduction next month, will maintain its current ceiling, and the reduction will be postponed to May 1 next year.